Literature DB >> 35606166

A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions.

Evan S Dellon1, Paneez Khoury2, Amanda B Muir3, Chris A Liacouras4, Ekaterina Safroneeva5, Dan Atkins6, Margaret H Collins7, Nirmala Gonsalves8, Gary W Falk9, Jonathan M Spergel10, Ikuo Hirano8, Mirna Chehade11, Alain M Schoepfer12, Calies Menard-Katcher13, David A Katzka14, Peter A Bonis15, Albert J Bredenoord16, Bob Geng17, Elizabeth T Jensen18, Robert D Pesek19, Paul Feuerstadt20, Sandeep K Gupta21, Alfredo J Lucendo22, Robert M Genta23, Girish Hiremath24, Emily C McGowan25, Fouad J Moawad26, Kathryn A Peterson27, Marc E Rothenberg28, Alex Straumann29, Glenn T Furuta30, Seema S Aceves31.   

Abstract

BACKGROUND & AIMS: Disease activity and severity of eosinophilic esophagitis (EoE) dictate therapeutic options and management, but the decision-making process for determining severity varies among practitioners. To reduce variability in practice patterns and help clinicians monitor the clinical course of the disease in an office setting, we aimed to create an international consensus severity scoring index for EoE.
METHODS: A multidisciplinary international group of adult and pediatric EoE researchers and clinicians, as well as non-EoE allergy immunology and gastroenterology experts, formed 3 teams to review the existing literature on histology, endoscopy, and symptoms of EoE in the context of progression and severity. A steering committee convened a 1-day virtual meeting to reach consensus on each team's opinion on salient features of severity across key clinicopathologic domains and distill features that would allow providers to categorize disease severity.
RESULTS: Symptom features and complications and inflammatory and fibrostenotic features on both endoscopic and histologic examination were collated into a simplified scoring system-the Index of Severity for Eosinophilic Esophagitis (I-SEE)-that can be completed at routine clinic visits to assess disease severity using a point scale of 0-6 for mild, 7-14 for moderate, and ≥15 for severe EoE.
CONCLUSIONS: A multidisciplinary team of experts iteratively created a clinically usable EoE severity scoring system denominated "I-SEE" to guide practitioners in EoE management by standardizing disease components reflecting disease severity beyond eosinophil counts. I-SEE should be validated and refined using data from future clinical trials and routine clinical practice to increase its utilization and functionality.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Eosinophilic esophagitis; complications; endoscopy; histology; severity; symptoms

Mesh:

Year:  2022        PMID: 35606166      PMCID: PMC9549868          DOI: 10.1016/j.jaci.2022.03.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   14.290


  106 in total

1.  Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.

Authors:  Alex Straumann; Sebastien Conus; Lukas Degen; Cornelia Frei; Christian Bussmann; Christoph Beglinger; Alain Schoepfer; Hans-Uwe Simon
Journal:  Clin Gastroenterol Hepatol       Date:  2011-01-28       Impact factor: 11.382

2.  Limitation of Symptoms as Predictors of Remission in Eosinophilic Esophagitis: The Need to Go Beyond Endoscopy and Histology.

Authors:  Alfredo J Lucendo; Javier Molina-Infante
Journal:  Gastroenterology       Date:  2016-01-23       Impact factor: 22.682

3.  RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Margaret H Collins; Yehudith Assouline-Dayan; Larry Evans; Sandeep Gupta; Alain M Schoepfer; Alex Straumann; Ekaterina Safroneeva; Michael Grimm; Heather Smith; Cindy-Ann Tompkins; Amy Woo; Robert Peach; Paul Frohna; Sheila Gujrathi; Darryl N Penenberg; Caiyan Li; Gregory J Opiteck; Allan Olson; Richard Aranda; Marc E Rothenberg; Evan S Dellon
Journal:  Gastroenterology       Date:  2018-11-02       Impact factor: 22.682

4.  Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.

Authors:  Alfredo J Lucendo; Stephan Miehlke; Christoph Schlag; Michael Vieth; Ulrike von Arnim; Javier Molina-Infante; Dirk Hartmann; Albert Jan Bredenoord; Constanza Ciriza de Los Rios; Stefan Schubert; Stefan Brückner; Ahmed Madisch; Jamal Hayat; Jan Tack; Stephen Attwood; Ralph Mueller; Roland Greinwald; Alain Schoepfer; Alex Straumann
Journal:  Gastroenterology       Date:  2019-03-26       Impact factor: 22.682

Review 5.  Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults.

Authors:  Alfredo J Lucendo; Javier Molina-Infante; Ángel Arias; Ulrike von Arnim; Albert J Bredenoord; Christian Bussmann; Jorge Amil Dias; Mogens Bove; Jesús González-Cervera; Helen Larsson; Stephan Miehlke; Alexandra Papadopoulou; Joaquín Rodríguez-Sánchez; Alberto Ravelli; Jukka Ronkainen; Cecilio Santander; Alain M Schoepfer; Martin A Storr; Ingrid Terreehorst; Alex Straumann; Stephen E Attwood
Journal:  United European Gastroenterol J       Date:  2017-01-23       Impact factor: 4.623

6.  Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis.

Authors:  Christopher Ma; Albert J Bredenoord; Evan S Dellon; Jeffrey A Alexander; Luc Biedermann; Malcolm Hogan; Leonardo Guizzetti; Guangyong Zou; David A Katzka; Mirna Chehade; Gary W Falk; Glenn T Furuta; Sandeep K Gupta; Amir F Kagalwalla; Alain M Schoepfer; Stephan Miehlke; Fouad J Moawad; Kathryn Peterson; Nirmala P Gonsalves; Alex Straumann; Joshua B Wechsler; Julie Rémillard; Lisa M Shackelton; Hector S Almonte; Brian G Feagan; Vipul Jairath; Ikuo Hirano
Journal:  Gastrointest Endosc       Date:  2022-02-01       Impact factor: 10.396

7.  Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score.

Authors:  Cary C Cotton; John T Woosley; Susan E Moist; Sarah J McGee; Alina Iuga; Nicholas J Shaheen; Evan S Dellon
Journal:  Endoscopy       Date:  2022-01-11       Impact factor: 9.776

Review 8.  Environmental factors and eosinophilic esophagitis.

Authors:  Elizabeth T Jensen; Evan S Dellon
Journal:  J Allergy Clin Immunol       Date:  2018-05-02       Impact factor: 10.793

9.  Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.

Authors:  Ikuo Hirano; Margaret H Collins; David A Katzka; Vincent A Mukkada; Gary W Falk; Robin Morey; Nirav K Desai; Lan Lan; James Williams; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2021-04-19       Impact factor: 13.576

10.  Dilation Modifies Association Between Symptoms and Esophageal Eosinophilia in Adult Patients With Eosinophilic Esophagitis.

Authors:  Ekaterina Safroneeva; Cary C Cotton; Alain M Schoepfer; Marcel Zwahlen; John T Woosley; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2020-12       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.